USA: +1 617 939 9497 | UK: +44 2039 962936 | EU: +34 607 939 266 info@sofpromed.com
Select Page

CRO for Global Real-World Data (RWD) Studies

Patricio Ledesma

Sofpromed's CEO and Founder. Global Director of Clinical Operations. 15+ years of experience in managing clinical trials.

19 November, 2026

Researcher reviewing a global network of patient records and clinical data for multinational real-world data studies.

By Patricio Ledesma, Founder and CEO, Sofpromed

Table of Contents

Real-World Data (RWD) has become one of the most valuable assets in modern healthcare research.

While randomized clinical trials remain the foundation for demonstrating efficacy and safety, regulators, payers, healthcare providers, and pharmaceutical companies increasingly rely on Real-World Data to understand how therapies perform in routine clinical practice.

This trend has accelerated significantly over the last decade, driven by advances in electronic health records, disease registries, hospital databases, and digital health technologies.

Having spent more than fifteen years managing international clinical research programs, I have witnessed firsthand the growing importance of Real-World Data studies.

I have also observed that many sponsors initially underestimate the operational complexity involved in conducting these projects, especially when they span multiple countries and healthcare systems.

On paper, an RWD study may appear simpler than a traditional interventional clinical trial because no investigational product is administered.

However, the reality is often very different.

International Real-World Data studies can involve dozens of countries, hundreds of investigators, thousands of patients, multiple ethics committees, diverse privacy regulations, and vast amounts of heterogeneous clinical data.

At Sofpromed, we have extensive experience supporting global Real-World Data initiatives, including large-scale multinational studies involving rare diseases and oncology populations.

Through our operational, regulatory, clinical data management, and project management expertise, we help sponsors transform complex healthcare data into meaningful scientific evidence.

In this article, I will discuss the main challenges associated with global Real-World Data studies, explain how Contract Research Organizations (CROs) help overcome those challenges, share lessons learned from a successful multinational rare tumor project supported by Sofpromed, and describe the operational factors that determine whether an RWD study succeeds or fails.

The Growing Importance of Real-World Data

Real-World Data refers to information related to patient health status and healthcare delivery that is routinely collected from sources outside traditional randomized clinical trials.

Common RWD sources include:

Source Type

Examples

Electronic Health Records (EHR)

Epic, Cerner, hospital information systems

Patient Registries

Oncology registries, rare disease registries

Insurance Claims Databases

Public and private payer databases

Laboratory Databases

Diagnostic testing platforms

Imaging Repositories

Radiology and pathology databases

Pharmacy Data

Dispensing and prescription records

Wearable Devices

Remote monitoring systems

Patient-Reported Outcomes

Quality-of-life assessments

RWD supports numerous healthcare objectives, including:

  • Post-marketing surveillance
  • Comparative effectiveness research
  • Health economics and outcomes research (HEOR)
  • Safety monitoring
  • Clinical practice evaluations
  • Regulatory decision making
  • Market access submissions
  • Rare disease research
  • Treatment pattern analyses

The increasing acceptance of Real-World Evidence by agencies such as the FDA, EMA, MHRA, Health Canada, PMDA, and many national reimbursement bodies has expanded the demand for robust multinational RWD studies.


Why Global RWD Studies Are So Challenging

Many sponsors believe that because patients are treated according to routine clinical practice, operational requirements are minimal.

In reality, setting up a multinational Real-World Data study often presents challenges similar to those encountered in interventional clinical trials.

The complexity arises from the need to harmonize data collection, regulatory compliance, ethics requirements, contracting processes, and operational execution across multiple jurisdictions.

The larger the study, the greater the challenge becomes.

Consider a rare disease registry involving:

  • 20 countries
  • 50 clinical sites
  • 5,000 patients
  • 10 years of longitudinal follow-up
  • Multiple data sources
  • Several languages

Without strong operational oversight, such projects can quickly encounter delays, budget overruns, poor-quality data, and inconsistent study execution.


Challenge #1: Country-Specific Ethics and Regulatory Requirements

One of the first obstacles sponsors encounter is the approval process.

Even though many Real-World Data studies are non-interventional, ethical oversight remains essential.

Requirements vary significantly between countries.

For example:

Country/Region

Typical Approval Requirements

European Union

Ethics Committee approval

United Kingdom

Research Ethics Committee review

United States

Institutional Review Board approval

Canada

Research Ethics Board approval

Brazil

CEP/CONEP review

Argentina

Provincial and local ethics approvals

Mexico

Institutional ethics review

Japan

Institutional ethics committees

In addition, some countries require specific approvals for:

  • Retrospective chart reviews
  • Use of anonymized records
  • Secondary use of health data
  • International data transfers
  • Registry establishment

Managing these submissions separately can overwhelm sponsors, particularly when dozens of sites are involved.

This is one of the areas where experienced CRO support becomes invaluable.


Challenge #2: Data Privacy and Data Transfer Regulations

Data privacy is often the single most underestimated challenge in global RWD programs.

Today, healthcare organizations face increasingly strict regulations governing patient information.

Examples include:

Region

Regulation

European Union

GDPR

United Kingdom

UK GDPR

United States

HIPAA

Brazil

LGPD

Canada

PIPEDA

Singapore

PDPA

Each regulation introduces specific requirements regarding:

  • Patient consent
  • Data storage
  • Data anonymization
  • Data transfer
  • Access rights
  • Security controls

Sponsors must ensure compliance across every participating country.

Failure to do so can result in:

  • Regulatory findings
  • Study delays
  • Contractual disputes
  • Data exclusion
  • Financial penalties

A CRO provides the infrastructure and expertise necessary to manage these complexities consistently.


Challenge #3: Identifying Appropriate Sites

Finding suitable investigators and institutions is often difficult, particularly for rare disease studies.

Successful sites must provide:

  • Adequate patient populations
  • Access to historical records
  • Research experience
  • Available personnel
  • Institutional support
  • Long-term commitment

For common diseases, site recruitment may be relatively straightforward.

For rare tumors, rare genetic conditions, or ultra-rare diseases, identifying qualified sites becomes significantly more difficult.

The challenge increases dramatically when:

  • Patients are geographically dispersed.
  • Different healthcare systems are involved.
  • Long-term follow-up is required.
  • Historical records cover many years.

Experienced CROs maintain extensive investigator networks that accelerate site selection activities.


Challenge #4: Site Contracts and Budget Negotiations

One of the greatest causes of startup delays in multinational studies is contracting.

Each institution typically has its own legal department, procurement process, financial requirements, and contractual templates.

Negotiations frequently involve:

  • Data ownership
  • Publication rights
  • Budget terms
  • Subject compensation
  • Privacy obligations
  • Intellectual property
  • Insurance requirements

A study involving fifty sites may require fifty separate negotiations.

Without dedicated contract specialists, startup timelines can easily extend by several months.

Professional CROs maintain contracting teams whose sole focus is accelerating agreement execution and site activation.


Challenge #5: Site Activation and Study Training

Even after ethics approvals and contracts are finalized, sites cannot begin enrolling subjects until proper activation procedures are completed.

Site activation typically includes:

  • Investigator training
  • Study documentation review
  • System access provisioning
  • Data entry training
  • User account creation
  • Registry procedures training
  • Data privacy compliance training

Poorly trained sites often generate:

  • Missing data
  • Data inconsistencies
  • Protocol deviations
  • Higher query rates
  • Delayed database locks

Proper startup procedures reduce these risks significantly.


Challenge #6: Data Standardization

One of the most difficult aspects of international RWD research involves standardizing data from diverse sources.

Different countries may use:

  • Different medical coding systems
  • Different laboratory units
  • Different disease classifications
  • Different treatment pathways
  • Different healthcare practices

For example, tumor staging information may be captured differently between hospitals in Spain, Germany, Brazil, and Argentina.

Similarly:

  • Laboratory values may use different units.
  • Historical records may vary in detail.
  • Medical terminology may differ substantially.

Without rigorous data standardization procedures, pooled analysis becomes unreliable.


Challenge #7: Data Quality Management

Many sponsors assume that because data originates from clinical practice, it is automatically reliable.

In reality, real-world datasets frequently contain:

  • Missing variables
  • Duplicate records
  • Incomplete follow-up
  • Coding inconsistencies
  • Documentation gaps
  • Historical inaccuracies

Effective data quality management requires structured processes including:

Data Review Activity

Objective

Query Management

Resolve discrepancies

Consistency Reviews

Verify data logic

Medical Coding Reviews

Standardize terminology

Data Reconciliation

Verify source alignment

Missing Data Reviews

Improve completeness

A dedicated CRO data management team becomes critical in maintaining study integrity.


The Role of a CRO in Global Real-World Data Studies

A CRO serves as the operational engine behind multinational RWD projects.

Sponsors define scientific objectives.

The CRO executes the study.

At Sofpromed, our role typically includes:

Regulatory Support

  • Ethics submissions
  • Privacy documentation
  • Regulatory correspondence
  • Approval tracking

Site Start-Up

  • Feasibility assessments
  • Site identification
  • Site selection
  • Site qualification

Contracting

  • Budget negotiations
  • Contract drafting
  • Legal coordination
  • Agreement execution

Site Activation

  • Site training
  • Documentation review
  • Study initiation

Clinical Data Management

  • Database development
  • Data cleaning
  • Query management
  • Medical coding

Project Management

  • Timeline tracking
  • Risk management
  • Vendor coordination
  • Sponsor communication

These integrated services allow sponsors to focus on strategic objectives while operational execution is managed efficiently.


Case Study: Global Rare Tumor Real-World Data Project

One of the most significant Real-World Data programs supported by Sofpromed involved a multinational study focused on rare tumors.

The project sought to collect long-term real-world clinical outcomes across Europe and Latin America.

Project Scope

Parameter

Details

Clinical Sites

50

Geographic Coverage

Europe and Latin America

Patients

Approximately 5,000

Disease Area

Rare tumors

Study Design

Real-world observational study

Follow-Up

Long-term outcomes

The sponsor faced several operational challenges:

  • Multiple languages
  • Diverse healthcare systems
  • Numerous ethics committees
  • Variable site capabilities
  • Complex contracting requirements
  • Large-scale data collection needs

Sofpromed was selected to provide comprehensive operational support.


Site Identification and Start-Up

The first phase focused on site selection and feasibility.

Our team leveraged established investigator networks across:

  • Spain
  • Italy
  • Portugal
  • Argentina
  • Brazil
  • Chile
  • Colombia
  • Additional participating countries

We evaluated:

  • Patient volume
  • Historical case availability
  • Investigator interest
  • Data accessibility
  • Local regulatory requirements

This process ensured that only qualified sites entered startup activities.


Contracting and Site Activation

Following site selection, Sofpromed managed:

  • Site contract negotiations
  • Budget discussions
  • Legal review coordination
  • Document collection
  • Site activation activities

Managing fifty sites across two continents required extensive coordination between investigators, hospital administrations, legal departments, and sponsor stakeholders.

Through centralized project management, startup timelines remained aligned with sponsor expectations.


Clinical Data Management

Clinical data management represented one of the most critical components of this project.

With approximately 5,000 rare tumor cases, data consistency was essential.

Our data management team performed:

Database Design

  • eCRF development
  • Validation rules creation
  • User role management

Data Cleaning

  • Query generation
  • Missing data review
  • Consistency checks

Medical Coding

  • Disease coding
  • Medication coding
  • Adverse event standardization

Quality Control

  • Ongoing data review
  • Trend analyses
  • Data reconciliation

These activities helped maintain the high-quality dataset required for downstream analyses.


Key Lessons Learned

Several operational lessons emerged from this project.

Early Feasibility Is Essential

Rare disease studies require accurate patient estimates.

Overestimating site performance can significantly impact timelines.

Contracting Often Determines Success

For multinational studies, site contracts frequently represent the largest startup bottleneck.

Early engagement with legal stakeholders reduces delays.

Data Management Should Start Early

Many sponsors invest heavily in enrollment planning while underestimating data management requirements.

Data quality strategies should be established before the first patient record is entered.

Communication Is Critical

Regular communication between:

  • Sponsor teams
  • Investigators
  • CRO project managers
  • Data management groups

helps prevent operational drift.


Key Operational Success Factors for RWD Studies

In my experience, successful Real-World Data studies share several common characteristics.

1. Strong Feasibility Assessment

Accurate site and patient estimates form the foundation of a successful project.

Poor feasibility assumptions often lead to enrollment delays and budget overruns.

2. Efficient Site Start-Up

Site activation speed can make the difference between success and failure.

Experienced CRO support significantly accelerates startup activities.

3. Centralized Project Management

Multinational studies require a central coordination structure capable of managing dozens of stakeholders simultaneously.

4. Robust Data Management

High-quality evidence depends upon high-quality data.

Data cleaning must be continuous rather than retrospective.

5. Consistent Communication

Structured governance combined with regular communication improves study performance across all participating sites.

6. Risk-Based Operational Oversight

Identifying operational risks early allows corrective actions before significant delays occur.

Why Sponsors Choose Sofpromed for Global RWD Programs

At Sofpromed, we understand that Real-World Data studies are operationally complex projects requiring a combination of regulatory expertise, startup experience, data management excellence, and global coordination.

Our teams have supported studies across:

  • Europe
  • North America
  • Latin America
  • Asia-Pacific
  • Middle East regions

Our experience includes:

  • Disease registries
  • Rare disease studies
  • Oncology programs
  • Post-marketing studies
  • Health economics projects
  • Long-term outcome registries

We provide flexible support models ranging from standalone data management services to fully integrated operational programs.

Our ability to coordinate international startup activities, negotiate site contracts, activate sites efficiently, and manage large-scale clinical datasets allows sponsors to generate reliable Real-World Evidence while minimizing operational risk.

Conclusion

Global Real-World Data studies are becoming increasingly important for pharmaceutical companies, biotechnology firms, medical device manufacturers, academic institutions, and healthcare organizations seeking to generate evidence beyond traditional clinical trials.

However, conducting successful multinational RWD programs requires far more than simply collecting patient information.

Sponsors must navigate ethics approvals, privacy regulations, site selection, contract negotiations, study startup, data standardization, quality management, and long-term operational oversight.

These challenges become even more significant when studies involve multiple countries, thousands of patients, and rare diseases.

From my experience managing international research programs, operational execution is often the difference between a successful Real-World Data study and one that struggles with delays, poor-quality data, and budget overruns.

At Sofpromed, we help sponsors overcome these challenges through comprehensive CRO services that include site start-up, contracting, site activation, project management, and clinical data management.

Our successful support of a multinational Real-World Data study involving 50 clinical sites across Europe and Latin America and approximately 5,000 rare tumor cases demonstrates how strong operational leadership, structured processes, and experienced teams can transform a highly complex international project into a successful evidence-generation program.

As the importance of Real-World Evidence continues to grow, I believe that sponsors who invest in operational excellence from the very beginning will be best positioned to generate reliable data, produce meaningful insights, and ultimately improve outcomes for patients worldwide.

Patricio Ledesma

Patricio Ledesma (B.Eng Concordia University, Montreal, Canada and Master’s Degree in Clinical Trials, University of Seville, Spain) is the Head of Clinical Operations and Founder at Sofpromed CRO. Patricio is a professional consultant providing comprehensive, one-stop expert advice and guidance to biotechnology and pharmaceutical companies worldwide in the field of clinical trials and drug development. He is personally and enthusiastically devoted to helping biotech Chief Executive, Operations, Scientific, Medical, and Regulatory Officers in the planning and execution of phase I-IV clinical trials across North America, Europe, Asia-Pacific, Latin America, and Middle East regions. You can contact Patricio at: +34 607 939 266  pledesma@sofpromed.com 

You may also be interested...

Patricio Ledesma

Patricio Ledesma (B.Eng Concordia University, Montreal, Canada and Master’s Degree in Clinical Trials, University of Seville, Spain) is the Head of Clinical Operations and Founder at Sofpromed CRO. Patricio is a professional consultant providing comprehensive, one-stop expert advice and guidance to biotechnology and pharmaceutical companies worldwide in the field of clinical trials and drug development. He is personally and enthusiastically devoted to helping biotech Chief Executive, Operations, Scientific, Medical, and Regulatory Officers in the planning and execution of phase I-IV clinical trials across North America, Europe, Asia-Pacific, Latin America, and Middle East regions. You can contact Patricio at: +34 607 939 266 pledesma@sofpromed.com